Skip to main content

Table 3 Baseline characteristics of AAV patients with and without excessive B cell differentiation by treatment group

From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

VariablesRituximab group, n = 34IV-CY group, n = 20p value
Excessive B cell differentiation++ 
n (%)16 (24.1%)18 (27.6%)8 (14.8%)12 (22.2%) 
Age (years)71.6 (8.3)69.6 (9.5)69.4 (8.6)71.7 (7.8)0.83
Gender, n (% female)8 (57.1%)11 (68.8%)4 (44.4%)8 (42.1%)0.67
Disease duration (month)2 (2–4)3 (1–7)3 (2–7)4 (1–6)0.70
New onset, n (%)16 (100.0%)18 (100.0%)8 (100.0%)12 (100.0%)1.00
ANCA-positive at diagnosis, n (%)
 Proteinase 3 ANCA3 (18.8%)1 (5.6%)0 (0.0%)0 (0.0%)0.15
 Myeloperoxidase-ANCA11 (68.8%)15 (83.3%)7 (87.5%)11 (91.7%)0.43
 Proteinase 3 + myeloperoxidase-ANCA1 (6.3%)2 (11.1%)1 (12.5%)0 (0.0%)0.65
ANCA-associated vasculitis type, n (%)    0.35
 MPA8 (50.0%)11 (61.1%)7 (87.5%)8 (66.7%) 
 GPA8 (50.0%)7 (38.9%)1 (12.5%)4 (33.3%) 
BVAS18.0 (5.6)16.9 (7.3)14.5 (4.5)15.4 (4.8)0.50
GC dose at baseline54.6 (11.0)57.7 (12.1)62.5 (22.4)61.0 (12.8)0.51
  1. Values listed as mean (SD) and median (minimum-maximum) unless otherwise stated. The statistical difference was determined by Bonferroni method, with chi-square test used for nominal variables. Difference with p < 0.05 was considered significant